Patents Assigned to Suzhou Yongxin Biological Science and Technology Co., Ltd
  • sDR5-Fc fusion protein mutant and use thereof
    Patent number: 10918739
    Abstract: The present disclosure discloses a human sDR5-Fc fusion protein in the preparation of adjuvant therapy for myocardial ischemia-reperfusion injury. The sDR5-Fc antibody fusion protein of the disclosure is prepared by connecting the 182 amino acids in DR5 extracellular domain with the human anti-Fc fragments. It has been tested that the sDR5-Fc antibody fusion protein of the disclosure can basically avoid Fc-mediated ADCC effect and can significantly reduce the area of myocardial infarction in rats of myocardial ischemia-reperfusion models.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 16, 2021
    Assignee: Suzhou Yongxin Biological Science and Technology Co., Ltd
    Inventor: Yuanfang Ma